Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 14/20 | 0.45 |
| ▸ | JAK2 | O60674 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998528 | 0.87 | JAK1 (0.48) | JAK1JAK2MEN1KMT2ANPC1 | |
| SCHEMBL17888217 | 0.77 | JAK1 (0.48) | JAK1JAK2MEN1KMT2ANPC1 | |
| SCHEMBL17886543 | 0.76 | JAK1 (0.47) | JAK1JAK2MEN1KMT2ANPC1 | |
| SCHEMBL21077850 | 0.74 | JAK1 (0.48) | JAK1JAK2MEN1KMT2ANPC1 | |
| SCHEMBL23442166 | 0.73 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL24148714 | 0.69 | QDPR (0.35) | — | |
| SCHEMBL20753888 | 0.68 | JAK1 (0.41) | JAK1JAK2MEN1KMT2ANPC1 | |
| SCHEMBL23627165 | 0.68 | QDPR (0.41) | MEN1KMT2ANPC1 | |
| SCHEMBL25633280 | 0.68 | MEN1 (0.36) | JAK1MEN1KMT2A | |
| SCHEMBL19998554 | 0.68 | JAK1 (0.40) | JAK1JAK2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MEN1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.